Table 1.
Baseline characteristics of evaluable MDS patients (n = 18)
| Patient characteristics | |
|---|---|
| Male | 11 (61 %) |
| Age | 70 (64, 75) |
| Race | |
| White | 16 (89 %) |
| Black | 1 (6 %) |
| Other | 1 (6 %) |
| Time from diagnosis to study consent (year) | 2.3 (1.4, 4.4) |
| ECOG performance status | |
| Fully active (0) | 9 (50 %) |
| Restricted from physically strenuous activity (1) | 9 (50 %) |
| Bone marrow biopsy karyotype | |
| Normal | 9 (50 %) |
| 11q deletion | 2 (11 %) |
| 20q deletion | 5 (28 %) |
| Trisomy 8 | 1 (6 %) |
| Trisomy 1 | 1 (6 %) |
| MDS classification | |
| RCMD | 10 (56 %) |
| RARS | 2 (11 %) |
| RCMD-RS | 2 (11 %) |
| RCUD | 2 (11 %) |
| CMML | 1 (6 %) |
| RAEB-1 | 1 (6 %) |
Results are presented as median (interquartile range [IQR]) or frequency. Some totals exceed 100 % due to rounding
CMML chronic myelomonocytic leukemia, RAEB-1 refractory anemia with excess blasts (EB), -1: cytopenias < 5 % blasts, no Auer rods, < 1 × 109/L monocytes in peripheral blood, RARS RA with ringed sideroblasts (RS), RC refractory cytopenia, RCMD RC with multilineage dysplasia (MD), RCUD RC with unilineage dysplasia (UD)